| 1 |
34667127 | Targeting the Pro-survival Protein BCL-2 to Prevent Breast Cancer. | 2022 Jan |
1 |
| 2 |
35432205 | Cellular Senescence in Diabetes Mellitus: Distinct Senotherapeutic Strategies for Adipose Tissue and Pancreatic β Cells. | 2022 |
1 |
| 3 |
33976278 | Acute toxicity analysis of an inhibitor of BCL2, Disarib, in rats. | 2021 May 11 |
1 |
| 4 |
31640928 | MicroRNA dysregulation and multi-targeted therapy for cancer treatment. | 2020 Jan |
1 |
| 5 |
32677976 | DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. | 2020 Jul 16 |
2 |
| 6 |
28663582 | BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. | 2018 Feb |
1 |
| 7 |
29118061 | Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression. | 2018 Jan 15 |
2 |
| 8 |
29386360 | Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC/BCL2 double-hit B cell lymphoma. | 2018 Jan 31 |
3 |
| 9 |
29666304 | Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. | 2018 Aug 15 |
1 |
| 10 |
29854301 | Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations. | 2018 Apr 27 |
1 |
| 11 |
29944468 | Induction of neutrophil apoptosis by a Bcl-2 inhibitor reduces particulate matter-induced lung inflammation. | 2018 Jun 26 |
1 |
| 12 |
30017199 | ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma. | 2018 Sep 10 |
1 |
| 13 |
30155839 | BH3 Mimetic ABT-199 Enhances the Sensitivity of Gemcitabine in Pancreatic Cancer in vitro and in vivo. | 2018 Dec |
2 |
| 14 |
28566329 | Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas. | 2017 Jul 15 |
1 |
| 15 |
28915653 | Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma. | 2017 Aug 22 |
1 |
| 16 |
27353420 | Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models. | 2016 Jun 28 |
2 |
| 17 |
27693384 | A novel inhibitor of BCL2, Disarib abrogates tumor growth while sparing platelets, by activating intrinsic pathway of apoptosis. | 2016 Dec 15 |
1 |
| 18 |
25880088 | BCL-2 is dispensable for thrombopoiesis and platelet survival. | 2015 Apr 16 |
1 |
| 19 |
26254443 | Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. | 2015 Sep 24 |
1 |